

WASHINGTON STATE VACCINE ADVISORY COMMITTEE (VAC)
RECOMMENDATION FOR USE OF INFLUENZA VACCINE

As unanimously agreed upon in the July 13, 2006 VAC meeting, the Committee recommends full acceptance of the Advisory Committee for Immunization Practices's (ACIP) recommendations for use of Influenza vaccine to vaccinate children in Washington State with special emphasis on the importance of vaccinating household contacts and out-of-home caregivers of children less than 6 months of age.

Advisory Committee on Immunization Practices (ACIP)
Recommendations for Influenza Vaccination of Children:

Eligible Groups for Inactivated Influenza Vaccine

All children aged 6 months through 18 years, with priority given to those listed below if available supplies are limited:

Children aged 6 months through 59 months.

Children and adolescents aged 5 through 18 years with chronic disorders of the pulmonary or cardiovascular systems, including asthma.

Children and adolescents aged 5 through 18 years who have required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus [HIV]).

Children and adolescents aged 5 through 18 years who have any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration.

Children and adolescents aged 5 through 18 years who are receiving long-term aspirin therapy and may therefore be at risk for developing Reye syndrome after influenza.

Children and adolescents aged 5 through 18 years who are residents of nursing homes and other chronic-care facilities that house persons at any age who have chronic medical conditions.

Adolescent females aged <19 years who will be pregnant during influenza season.

Children and adolescents aged **5 through 18 years** who are household contacts of persons in the following high-risk groups:

1. Any children less than 5 years old;
2. Children or adolescents in any of the other groups listed above;
3. Any person 50 years or older;
4. Adults with chronic disorders of the pulmonary or cardiovascular systems;

5. Adults who have required regular medical follow-up or hospitalization during the preceding year for chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus [HIV]).

Eligible Groups for Live Attenuated Influenza Vaccine

All healthy children and adolescents aged 5 years through 18 years, with priority given to those listed below if available supplies are limited:

Household contacts of persons in the following high-risk groups provided that the contacts are not severely immunocompromised (e.g., patients with hematopoietic stem cell transplants) and requiring care in a protective environment:

1. Any children less than 5 years old;
2. Children or adolescents in any of the other groups listed above;
3. Any person 50 years or older;
4. Adults with chronic disorders of the pulmonary or cardiovascular systems;
5. Adults who have required regular medical follow-up or hospitalization during the preceding year for chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus [HIV]).

The following children and adolescents should **NOT** be vaccinated with LAIV:

Children aged <5 years;*

Persons with asthma, reactive airways disease or other chronic disorders of the pulmonary or cardiovascular systems; persons with other underlying medical conditions, such as the metabolic diseases diabetes, renal dysfunction, and hemoglobinopathies; or persons with known or suspected immunodeficiency diseases or who are receiving immunosuppressive therapies;*

Children or adolescents receiving aspirin or other salicylates (because of the association of Reye syndrome with wild-type influenza infection);*

Persons with a history of GBS;

Pregnant women;* or

Persons with a history of hypersensitivity, including anaphylaxis, to any of the components of LAIV or to eggs.

* These persons should receive inactivated influenza vaccine if age ≥ 6 months.

Recommended Influenza Vaccine Schedule

<u>Age Group*</u>	<u>Number of doses</u>
6 months - 8 years	1 or 2¶
>8 years	1

Recommended Dosage Intervals

<u>Vaccine</u>	<u>Minimum Age*</u>	<u>Minimum interval dose 1 to 2 (where applicable) ¶</u>
Influenza, inactivated	6 months	28 days
Influenza, live attenuated	5 years	42 days

* Fluzone[®] influenza virus vaccine (Sanofi Pasteur, Inc.) is approved for use in all persons aged ≥ 6 months. Fluvirin[™] purified surface antigen vaccine (Chiron Vaccines, Ltd.) is approved for use only among persons aged ≥ 4 years. Fluarix[™] influenza virus vaccine (GlaxoSmithKline Biologicals) is approved for use only among persons aged ≥ 18 years. FluMist[™] live, attenuated influenza vaccine (MedImmune Vaccines, Inc.) is approved for use only among healthy persons aged 5-49 years.

Two doses are recommended for children <9 years of age who are receiving influenza vaccine for the first time.

NOTE: Use of brand names is not meant to preclude the use of other licensed influenza vaccines.

Recommended Dosages

Refer to product package inserts.

Contraindications and Precautions

The following conditions are contraindications to administration of influenza vaccine:

- 1. Allergy to vaccine components**
Anaphylactic reaction to the vaccine or a constituent of the vaccine (e.g. eggs).
- 2. Moderate or severe illnesses with or without fever**
Persons with moderate or severe illness should be immunized as soon as they have recovered from the acute phase of the illness. Minor illnesses (e.g., upper respiratory tract infection, allergic rhinitis) with or without fever should not contraindicate the use of influenza vaccine (either inactivated or live, attenuated vaccine).

The following conditions are precautions to receipt of influenza virus vaccine:

- 1. History of Guillain-Barré Syndrome following influenza vaccination.**